JP2012507020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507020A5 JP2012507020A5 JP2011533626A JP2011533626A JP2012507020A5 JP 2012507020 A5 JP2012507020 A5 JP 2012507020A5 JP 2011533626 A JP2011533626 A JP 2011533626A JP 2011533626 A JP2011533626 A JP 2011533626A JP 2012507020 A5 JP2012507020 A5 JP 2012507020A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- assay
- fragment
- metabolic syndrome
- copeptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003556 assay Methods 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 23
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 18
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 18
- 238000000034 method Methods 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 14
- 206010012601 diabetes mellitus Diseases 0.000 claims 13
- 102400000060 Copeptin Human genes 0.000 claims 9
- 101800000115 Copeptin Proteins 0.000 claims 9
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 9
- 102400000059 Arg-vasopressin Human genes 0.000 claims 7
- 101800001144 Arg-vasopressin Proteins 0.000 claims 7
- 238000004458 analytical method Methods 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 238000003018 immunoassay Methods 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
- 101800004490 Endothelin-1 Proteins 0.000 claims 2
- 102100034296 Natriuretic peptides A Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 108010091794 preprovasopressin Proteins 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 102400000687 Big endothelin-1 Human genes 0.000 claims 1
- 101800001398 Big endothelin-1 Proteins 0.000 claims 1
- 108010008126 C-terminal proendothelin-1 Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000012192 Cystatin C Human genes 0.000 claims 1
- 108010061642 Cystatin C Proteins 0.000 claims 1
- 102400000686 Endothelin-1 Human genes 0.000 claims 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims 1
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 claims 1
- 101000585365 Homo sapiens Sulfotransferase 2A1 Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- -1 NT-proET-1 Proteins 0.000 claims 1
- 101710187800 Natriuretic peptides A Proteins 0.000 claims 1
- 102100036836 Natriuretic peptides B Human genes 0.000 claims 1
- 101710187802 Natriuretic peptides B Proteins 0.000 claims 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 claims 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims 1
- 108010048233 Procalcitonin Proteins 0.000 claims 1
- 102100029867 Sulfotransferase 2A1 Human genes 0.000 claims 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 claims 1
- 238000004364 calculation method Methods 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000035487 diastolic blood pressure Effects 0.000 claims 1
- 238000006073 displacement reaction Methods 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 1
- 108010012004 proadrenomedullin Proteins 0.000 claims 1
- 102000034567 proadrenomedullin Human genes 0.000 claims 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims 1
- 108010072272 proendothelin 1 Proteins 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229960003726 vasopressin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168096.9 | 2008-10-31 | ||
| EP08168096 | 2008-10-31 | ||
| PCT/EP2009/007923 WO2010049179A1 (en) | 2008-10-31 | 2009-10-29 | Arginine vasopressin pro-hormone as predictive biomarker for diabetes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042777A Division JP6055005B2 (ja) | 2008-10-31 | 2015-03-04 | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507020A JP2012507020A (ja) | 2012-03-22 |
| JP2012507020A5 true JP2012507020A5 (enExample) | 2012-12-06 |
| JP5785086B2 JP5785086B2 (ja) | 2015-09-24 |
Family
ID=40445457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533626A Active JP5785086B2 (ja) | 2008-10-31 | 2009-10-29 | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン |
| JP2015042777A Active JP6055005B2 (ja) | 2008-10-31 | 2015-03-04 | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042777A Active JP6055005B2 (ja) | 2008-10-31 | 2015-03-04 | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9116153B2 (enExample) |
| EP (2) | EP3199951B1 (enExample) |
| JP (2) | JP5785086B2 (enExample) |
| CN (3) | CN102317788A (enExample) |
| DK (1) | DK3199951T3 (enExample) |
| ES (2) | ES2645688T3 (enExample) |
| WO (1) | WO2010049179A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| EP2016394A4 (en) | 2006-04-04 | 2013-04-24 | Singulex Inc | METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES |
| DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| US20130149386A1 (en) * | 2011-12-07 | 2013-06-13 | Region Nordjylland | Cd36 as biomarker for steatosis |
| US20130338027A1 (en) * | 2012-06-15 | 2013-12-19 | Nuclea Biotechnologies, Inc. | Predictive Markers For Cancer and Metabolic Syndrome |
| JP6196034B2 (ja) | 2012-12-20 | 2017-09-13 | ライオン株式会社 | 高血糖リスク判定用マーカーペプチドおよびその用途 |
| CN103266089A (zh) * | 2013-05-09 | 2013-08-28 | 南京医科大学第一附属医院 | 抗人和肽素单克隆抗体mcco1及其应用 |
| US20160097781A1 (en) * | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
| CA3134929A1 (en) * | 2019-03-28 | 2020-10-01 | Lundoch Diagnostics AB | Use of follistatin in type 2 diabetes risk prediction |
| CN113238063A (zh) * | 2021-05-31 | 2021-08-10 | 迈克生物股份有限公司 | Gdf15评估代谢综合征患者进展为心血管疾病的应用 |
| CN113248590B (zh) * | 2021-06-24 | 2021-09-10 | 天津奇云诺德生物医学有限公司 | 一种NT-proBNP蛋白抗原决定簇多肽及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606016D0 (en) * | 1996-03-22 | 1996-05-22 | Smithkline Beecham Plc | Novel use |
| DE60335387D1 (de) * | 2002-07-16 | 2011-01-27 | Woomera Therapeutics Inc | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen |
| EP1673465A4 (en) * | 2003-09-29 | 2008-04-30 | Biosite Inc | PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| US20070218519A1 (en) * | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| JP5855332B2 (ja) * | 2006-10-18 | 2016-02-09 | アクセラ インコーポレーテッド | 広い濃度範囲にわたる複数アナライトの光回折による測定 |
| JP5320294B2 (ja) * | 2006-10-26 | 2013-10-23 | ベー.エル.アー.ハー.エム.エス ゲーエムベーハー | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンiiを使用する、急性冠動脈症候群についてのリスク層化 |
| WO2008128352A1 (en) * | 2007-04-19 | 2008-10-30 | Axela, Inc. | Methods and compositions for signal amplification |
-
2009
- 2009-10-29 JP JP2011533626A patent/JP5785086B2/ja active Active
- 2009-10-29 EP EP16205552.9A patent/EP3199951B1/en active Active
- 2009-10-29 CN CN2009801438824A patent/CN102317788A/zh active Pending
- 2009-10-29 CN CN201610269547.0A patent/CN106153943B/zh active Active
- 2009-10-29 CN CN201310681318.6A patent/CN103713137A/zh active Pending
- 2009-10-29 ES ES09744978.9T patent/ES2645688T3/es active Active
- 2009-10-29 DK DK16205552.9T patent/DK3199951T3/da active
- 2009-10-29 ES ES16205552T patent/ES2772930T3/es active Active
- 2009-10-29 WO PCT/EP2009/007923 patent/WO2010049179A1/en not_active Ceased
- 2009-10-29 US US13/126,798 patent/US9116153B2/en active Active
- 2009-10-29 EP EP09744978.9A patent/EP2356463B1/en active Active
-
2015
- 2015-03-04 JP JP2015042777A patent/JP6055005B2/ja active Active
- 2015-06-25 US US14/750,201 patent/US9952229B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012507020A5 (enExample) | ||
| Khan et al. | N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients | |
| JP5718981B2 (ja) | 原発性慢性腎臓疾患の進行についての予後バイオマーカー | |
| DK2823314T3 (en) | Predicting outcome in patients with chronic obstructive pulmonary disease | |
| Emdin et al. | Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure | |
| JP5711131B2 (ja) | 最初の有害事象の予測のためのバイオマーカー | |
| JP5945063B2 (ja) | 慢性心不全が疑われる患者における有害事象の予後 | |
| JP6055005B2 (ja) | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン | |
| CN103884841A (zh) | 利用新颖标志物CT-proADM进行诊断和危险分层 | |
| EP1888765A2 (en) | Methods and compositions for the diagnosis of venous thromboembolic disease | |
| JP2010520442A (ja) | Nyhai患者についてのナトリウム利尿ペプチドによる心機能不全の診断および危険性層化 | |
| WO2010077654A1 (en) | Combined natriuretic peptide assays | |
| Chen et al. | Increased serum 2-oxoglutarate associated with high myocardial energy expenditure and poor prognosis in chronic heart failure patients | |
| Breidthardt et al. | The novel marker LTBP2 predicts all-cause and pulmonary death in patients with acute dyspnoea | |
| RU2011103526A (ru) | Диагностирование хронической обструктивной болезни легких (хобл) | |
| Pervez et al. | Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study | |
| Chien et al. | Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP | |
| Mok et al. | Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction | |
| Choi et al. | The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients | |
| WO2024119898A1 (zh) | 血清可溶性st2在制备预测主动脉夹层患者预后产品中的应用及相关预测装置 | |
| CN101600967B (zh) | 和肽素或后叶激素运载蛋白ii在制备急性冠状动脉综合征危险性分级试剂盒的用途 | |
| US20160299154A1 (en) | Biomarker for cardiac disorders | |
| EP3918343B1 (en) | Method to predict treatment response in patients with nocturnal enuresis | |
| Feola et al. | Comparison between immunoradiometric and fluorimetric brain natriuretic peptide determination in patients with congestive heart failure | |
| van Hateren et al. | Copyright (C) 2011 by The American Association for Clinical Chemistry |